EUVIMEDEUVIMED entdecken
Crossref

Financial hardship and cost‐related nonadherence to medication in patients with liver disease in the United States

Donghee Kim iD, Richie Manikat iD, Karn Wijarnpreecha iD, Aijaz Ahmed iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Donghee Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA. Hauptthemen laut MEDLINE: COVID-19, Financial Stress, Liver Diseases, Drug Monitoring. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Economic hardship associated with chronic liver disease (CLD) may delay timely access to healthcare.

Aim

To estimate the national burden of financial hardship across the spectrum of CLD in the United States (US) during the coronavirus disease 2019 (COVID‐19) pandemic.

Methods

A cross‐sectional analysis was performed using the 2020–2021 US National Health Interview Survey database. The questionnaire defined financial hardship from medical bills and cost‐related nonadherence to medications in patients with CLD. We used weighted survey analysis to obtain the national estimates.

Results

While 6.9% (95% confidence interval [CI]: 6.7%–7.2%) out of 60,689 US adults (weighted sample: 251 million) reported financial hardship and inability to pay medical bills; 10.6% (95% CI: 8.3%–13.4%), 18.2% (95% CI: 14.5%–22.6%), 22.6% (95% CI: 11.0%–41.0%) with hepatitis, CLD/cirrhosis, and liver cancer experienced an inability to pay their medical bills due to financial hardship, respectively. 19.8% (95% CI: 15.9%–24.5%) and 23.3% (95% CI: 12.5%–39.3%) with CLD/cirrhosis and liver cancer, respectively experienced cost‐related nonadherence to medications, compared to a tenth of US adults (10.7%, 95% CI: 10.3%–11.2%). CLD/cirrhosis demonstrated an independent association with financial hardship from medical bills and cost‐related nonadherence to medications. Overall, these disparities were more pronounced in individuals aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Financial StressLiver DiseasesDrug MonitoringHumansUnited StatesCross-Sectional StudiesMaleFemaleMiddle AgedAdultAgedCost of IllnessSARS-CoV-2Young AdultAdolescentChronic DiseaseHealth ExpendituresHealth Services Accessibility

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
  • Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, Arizona, USA.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Banner University Medical Center, Phoenix, Arizona, USA.

ORCID-Profile: Donghee Kim, Richie Manikat, Karn Wijarnpreecha, Aijaz Ahmed

Zitieren

APA

Kim, D., Manikat, R., Wijarnpreecha, K., & Ahmed, A. (2024). Financial hardship and cost‐related nonadherence to medication in patients with liver disease in the United States. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18122

Vancouver

Kim D, Manikat R, Wijarnpreecha K, Ahmed A. Financial hardship and cost‐related nonadherence to medication in patients with liver disease in the United States. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18122

BibTeX
@article{Kim2024,
  author = {Kim, Donghee and Manikat, Richie and Wijarnpreecha, Karn and Ahmed, Aijaz},
  title = {Financial hardship and cost‐related nonadherence to medication in patients with liver disease in the United States},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18122}
}
Kostenlos starten →